BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 16, Issue 14
  • This Article
Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article
©2010 Baishideng.
World J Gastroenterol. Apr 14, 2010; 16(14): 1765-1771
Published online Apr 14, 2010. doi: 10.3748/wjg.v16.i14.1765
Table 1 Clinical characteristics of patients
Characteristicn (%)
Total90 (100.0)
Gender (M/F)59 (65.6)/31 (34.4)
Median age (yr)48 (range: 16-71)
Underlying disease
Multiple myeloma46 (51.1)
Hodgkin’s lymphoma23 (25.6)
Non-Hodgkin’s lymphoma15 (4.4)
Acute myeloblastic leukemia4 (4.4)
Acute lymphoblastic leukemia1 (1.1)
Primitive neuroectodermal tumor1 (1.1)
Conditioning regimen
Melphalan47 (52.2)
BEAM35 (38.9)
Busulfex-Cy4 (4.4)
Busulfex-Melphalan1 (1.1)
TBI-Cy-Thiotepa1 (1.1)
Thiotepa-Cy-Bu1 (1.1)
Z-BEAM1 (1.1)
BEAM: The combination of Carmustine (BCNU), Etoposide, Cytarabine (Ara-C) and Melphalan; Z-BEAM: The combination of Ybritumomab Tiuxetan (Zevalin®), Carmustine (BCNU), Etoposide, Cytarabine (Ara-C) and Melphalan; Cy: Cyclophosphamide; TBI: Total body irradiation.
Full Size Table
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.